1. Indications and Usage
\nPlaque Psoriasis:
\nIndicated for adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
\nPsoriatic Arthritis:
\nIndicated for adult patients with active psoriatic arthritis, alone or in combination with methotrexate.
\nOral and Genital Ulcers:
\nIndicated for oral ulcers in patients with Beh\u00e7et’s disease and genital ulcers in patients with Beh\u00e7et’s disease.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Oral Use ONLY.
\nRecommended Dosage (Psoriasis\/PsA):
\nDose: 30 mg twice daily, approximately 12 hours apart.
\nDose Titration: To minimize gastrointestinal side effects, the dose is titrated over 5 days:
\nDay 1: 10 mg (morning).
\nDay 2: 10 mg (morning and evening).
\nDay 3: 10 mg (morning), 20 mg (evening).
\nDay 4: 20 mg (morning and evening).
\nDay 5: 20 mg (morning), 30 mg (evening).
\nDay 6 and thereafter: 30 mg (morning and evening).
\nAdministration Instructions:
\nSwallow tablets whole; do not crush, chew, or split.
\nCan be taken with or without food.
\nRenal Impairment:
\nSevere Renal Impairment (CLcr <30 mL\/min) or ESRD: The recommended dose is 30 mg once daily. No titration is required for the evening dose (omit).
\n3. Mechanism of Action
\nPDE4 Inhibition:
\nApremilast is an intracellular enzyme inhibitor that selectively inhibits phosphodiesterase 4 (PDE4), the major cAMP-degrading enzyme in immune cells.
\nAnti-inflammatory Effect:
\nBy inhibiting PDE4, intracellular cAMP levels increase, leading to the downregulation of pro-inflammatory mediators (e.g., TNF-\u03b1, IL-17, IL-23) and upregulation of anti-inflammatory mediators (e.g., IL-10).
\n4. Safety and Warnings
\nWeight Loss:
\nWeight loss has been observed. Monitor weight periodically. Discontinue if significant, unexplained weight loss occurs.
\nDepression and Mood Changes:
\nDepression, suicidal ideation, and mood changes have been reported. Patients with a history of depression should be monitored closely.
\nDrug Interactions:
\nConcomitant use with strong CYP450 inducers (e.g., rifampin) may decrease efficacy.
\nUpper Respiratory Tract Infections:
\nIncreased incidence of upper respiratory tract infections has been reported.
\nAdverse Reactions
\nMost Common:
\nDiarrhea, nausea, headache, vomiting, and upper respiratory tract infection.
\nOther:
\nNasopharyngitis, insomnia, and dyspepsia.
\nDrug Interactions
\nCYP450 Inducers:
\nStrong inducers of CYP3A4 (e.g., rifampin, phenobarbital) can significantly reduce apremilast exposure and efficacy.
\nSubstrates:
\nApremilast does not significantly inhibit or induce major CYP enzymes at clinically relevant concentrations.
\nPharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Apremilast.
\nAvailable Strength: 10 mg, 20 mg, 30 mg tablets.
\nAppearance: Pink (10 mg), Brown (20 mg), Light Brown (30 mg) diamond-shaped film-coated tablets.
\nStorage: Store at 20\u00b0C\u201325\u00b0C (68\u00b0F\u201377\u00b0F); excursions permitted to 15\u00b0C\u201330\u00b0C (59\u00b0F\u201386\u00b0F).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u6b27\u6cf0\u4e50 \u00ae\uff08Otezla\u00ae\uff09
\n\u2022 Generic Name: Apremilast
\n\u2022 Strength: 10mg\u300120mg\u300130mg\uff08Combination pack: 10 mg \u00d7 4 tablets + 20 mg \u00d7 4 tablets + 30 mg \u00d7 19 tablets, total 27 tablets per box\uff09
\n\u2022 Manufacturer: Patheon Inc.
\n\u2022 Marketing Authorization Holder: Amgen Inc. (USA); domestic filing entity: Amgen (China) Co., Ltd.
\n\u2022 Approval Date in China: August 17, 2021
\n\u2022 Registration Number: \u56fd\u836f\u51c6\u5b57 HJ20210066
\n\u2022 Storage: Store at 20\u00b0C\u201325\u00b0C (68\u00b0F\u201377\u00b0F) in the original package, protected from light and moisture. Brief exposure to 15\u00b0C\u201330\u00b0C (59\u00b0F\u201386\u00b0F) is permitted. Keep out of reach of children.<\/p>\n
Price&Cost:Contact Us now for the best price of Apremilast\uff08Otezla\uff09<\/p>\n","protected":false},"featured_media":3937,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27],"product_tag":[],"class_list":["post-3936","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n